End-of-day quote
Korea S.E.
03:30:00 27/05/2024 am IST
5-day change
1st Jan Change
14,790
KRW
-1.92%
-0.54%
-13.46%
Anterogen Co.,Ltd. announced that it has received KRW 18 billion in funding
Anterogen Co.,Ltd. (KOSDAQ:A065660) announced that it has received a private placement of 2nd series unregistered and unsecured private convertible bonds for gross proceeds of KRW 18,000,000,000 on April 11, 2018. The bond carries a coupon of zero percent and would mature on April 11, 2021. The bonds are 100% convertible into 105,100 common shares at a fixed conversion price of KRW 171,264 per share. The convertible period is from April 11, 2019 to March 27, 2021. The transaction has been approved by the board of directors of the company.
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
12/23/12
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
08/21/08
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
05/21/05
CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding
24/20/24
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding
23/20/23
CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion.
26/20/26
CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
07/19/07
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
25/19/25
CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
26/19/26
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
15/19/15
CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding
01/19/01
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding
24/19/24
CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm
20/18/20
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor
08/18/08
CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
31/18/31
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
04/18/04
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding
12/18/12
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from a group of investors.
11/18/11
CI
EM-Tech Co., Ltd. announced that it has received KRW 14 billion in funding from Anterogen Co.,Ltd.
11/18/11
CI
Anterogen Co.,Ltd. announced that it has received KRW 18 billion in funding
11/18/11
CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from Company K Partners Limited
29/17/29
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from Company K Partners Limited
26/17/26
CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from EM-Tech. Co., Ltd.
27/17/27
CI
EM-Tech. Co., Ltd. announced that it has received KRW 7.82 billion in funding from Anterogen Co.,Ltd.
26/17/26
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from EM-Tech. Co., Ltd.
25/17/25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
More about the company
1st Jan change
Capi.
-13.46% 106M -1.64% 90.28B -1.84% 39.5B -15.83% 31.71B +61.72% 26.41B -21.68% 14.34B -8.73% 12.89B -10.32% 11.8B -45.77% 10.95B +3.15% 8.85B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1